xarelto

By: admin Oct 16

A new study suggests that bleeding events while using Xarelto may increase if other medications are also being used. The study found those containing amiodarone (Rifadin, Diflucan, and Dilantin) to be the most severe. How many more drug combinations are there that have not been discovered yet? When will the FDA take a stand and remove this dangerous blood thinner from the shelves?

About Xarelto

Approved by the FDA in 2011, Xarelto is used to reduce the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Manufacturers Bayer and Janssen promote the drug has the gold standard for anticoagulants. However, it may be more dangerous than other medications on the market since there is no antidote.

New Xarelto Study

According to a paper published in the Journal of American Medical Association (JAMA), researchers from Taiwan analyzed data on 91,000 patients who were using anticoagulants, including Xarelto, Eliquis, and Pradaxa, either alone or with other medications.

Their findings indicated that patients who took the anti-fungal medication Diflucan in combination with Xarelto were 25% more likely to suffer a major bleeding event.

Xarelto is a dangerous medication that continues to become even more dangerous as we learn different medication combinations. When will the FDA take a stand a recall this harmful drug?

Still No Xarelto Recall

As of October 2017, the FDA has not recalled Xarelto despite its potential to cause harm. In 2011, some FDA scientists did not even want to approve the drug in the first place. They felt patients were at a greater risk of stroke or bleeding when using Xarelto than the trusted warfarin. In one Xarelto clinical trial, 30 days after the study ended Xarelto subjects had experienced 22 strokes while warfarin users had experienced just six.

Seek Justice

Thousands of patients are speaking out against Xarelto. They decided to take a stand and ask for compensation from the manufacturers Bayer and Janssen. They feel these companies are profiting on their pains and their loved ones’ deaths. We are representing many of these people, and we are still accepting new clients in all 50 states.

Xarelto lawsuits are similar to lawsuits over Pradaxa, another newer-generation anticoagulant. Michael Brady Lynch, the founder of The Michael Brady Lynch Firm is leading the country in Pradaxa lawsuits. Michael was a member of the Plaintiff’s Steering Committee in the Pradaxa Multi-District Litigation and was instrumental in securing the $650 million settlement for those injured by Pradaxa’s uncontrollable bleeding. Mr. Lynch continues to be a leader in Pradaxa litigation nationwide in representing those who continue to suffer uncontrollable bleeding events from Pradaxa.